Key facts
- Operator of a therapeutics platform intended to research, develop, manufacture, and sell drugs for nucleic acid medicine.
- It has raised $1.3M; the latest was Early Stage VC in Jul 2024.
- Notable investors include Japan External Trade Organization, Intellectual Property Acceleration Program for Startups, NCB Capital (Fukuoka), QB Capital, Waseda University Ventures.
- Status: Privately Held (backing).
- ·Watch ANRis: the Monday email on marks, rounds and moves
Funding rounds
No funding rounds for ANRis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ANRis
Operator of a therapeutics platform intended to research, develop, manufacture, and sell drugs for nucleic acid medicine. The company's platform enables the precise targeting of only mutated genes, overcoming the limitations of conventional siRNA approaches that can suppress normal mRNA by selectively silencing disease-causing genes without disrupting normal cellular processes, enabling patients to access transformative treatments.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2023
- Employees
- 3
- Website
- anris.jp/
- Ownership
- Privately Held (backing)
ANRis doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.